www.fdanews.com/articles/82267-guidant-updated-to-buy
GUIDANT UPDATED TO 'BUY'
November 8, 2005
Analyst Glenn Novarro of Banc of America Securities upgrades Guidant from "neutral"
to "buy," while reducing his estimates for the company. The target
price has been reduced from $69 to $66.
Newratings